A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
Phoenix/Scottsdale, Ariz., Jacksonville, Fla., Rochester, Minn.
Open for Enrollment
Why is this study being done?
SYMPHONY is prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study of the PAH-SYMPACT, a new quality of life questionnaire for patients with pulmonary arterial hypertension. Patients will be in the study for 5 1/2 months, 4 months of which they will receive macitentan, 10 mg, once daily.
The primary objectives are to demonstrate the final content validity of the PAH SYMPACT instrument, to demonstrate the psychometric characteristics of reliability and construct validity of the PAH-SYMPACT instrument, and to demonstrate the ability of the PAH SYMPACT instrument to detect change. The secondary objective is to assess the safety of macitentan in patients with pulmonary arterial hypertension. The exploratory objective is to explore the effects of macitentan on PAH symptoms and their impact (as measured by the PAH-SYMPACT) in patients with pulmonary arterial hypertension.
Who can I contact for additional information about this study?
Rochester: Robert Frantz 507-284-2511
LuAnne Koenig (507) 284-4298
Scottsdale: Robert L Scott 480-342-2376
Arcenio Galindo (480) 342-3987
Jacksonville: Charles Burger 904-953-2000
Shannon Kennedy (904) 953-8557